Vinita Takiar1, K Ranh Voong1, Dan S Gombos2, Firas Mourtada3, Laura A Rechner4, Ann A Lawyer4, William H Morrison1, Adam S Garden1, Beth M Beadle5. 1. Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. 2. Department of Ophthalmology, University of Texas MD Anderson Cancer Center, Houston, Texas. 3. Department of Radiation Oncology, Helen F. Graham Cancer Center, Christiana Care Health System, Newark, Delaware, and Thomas Jefferson University, Philadelphia, Pennsylvania; Department of Radiation Physics, University of Texas MD Anderson Cancer Center, Houston, Texas. 4. Department of Radiation Physics, University of Texas MD Anderson Cancer Center, Houston, Texas. 5. Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: bbeadle@mdanderson.org.
Abstract
PURPOSE: Both iodine-125 ((125)I) Collaborative Ocular Melanoma Study and ruthenium-106 ((106)Ru) eye plaques can achieve excellent tumor control in patients diagnosed with uveal melanoma. We analyzed our single institutional experience in the management of ocular melanoma treated with either (125)I or (106)Ru plaque brachytherapy. METHODS AND MATERIALS: The records of 107 patients with uveal melanoma treated with either (106)Ru (n = 40) or (125)I (n = 67) plaque brachytherapy between 2000 and 2008 were retrospectively reviewed. Tumor control parameters and toxicity were assessed. RESULTS: Actuarial 5-year rates of local control, progression-free survival, and overall survival with (106)Ru were 97%, 94%, and 92%, respectively. For (125)I, these values were 83%, 65%, and 80%. In the subset of patients with tumor apex height ≤5 mm (36 (125)I and 40 (106)Ru), there was no difference in overall survival; however, progression-free survival was significantly improved with (106)Ru (P = .02). Enucleation-free survival was significantly different between the 2 subsets, with no enucleations in the (106)Ru cohort (P = .02). Patients treated with (106)Ru experienced reduced retinopathy (P = .03) and cataracts (P < .01). CONCLUSIONS: Both (125)I and (106)Ru eye plaque brachytherapy treatment result in encouraging tumor control for patients with uveal melanoma. We demonstrate that (106)Ru offers these benefits with reduced toxicity in patients treated for uveal melanomas ≤5 mm in apical height.
PURPOSE: Both iodine-125 ((125)I) Collaborative Ocular Melanoma Study and ruthenium-106 ((106)Ru) eye plaques can achieve excellent tumor control in patients diagnosed with uveal melanoma. We analyzed our single institutional experience in the management of ocular melanoma treated with either (125)I or (106)Ru plaque brachytherapy. METHODS AND MATERIALS: The records of 107 patients with uveal melanoma treated with either (106)Ru (n = 40) or (125)I (n = 67) plaque brachytherapy between 2000 and 2008 were retrospectively reviewed. Tumor control parameters and toxicity were assessed. RESULTS: Actuarial 5-year rates of local control, progression-free survival, and overall survival with (106)Ru were 97%, 94%, and 92%, respectively. For (125)I, these values were 83%, 65%, and 80%. In the subset of patients with tumor apex height ≤5 mm (36 (125)I and 40 (106)Ru), there was no difference in overall survival; however, progression-free survival was significantly improved with (106)Ru (P = .02). Enucleation-free survival was significantly different between the 2 subsets, with no enucleations in the (106)Ru cohort (P = .02). Patients treated with (106)Ru experienced reduced retinopathy (P = .03) and cataracts (P < .01). CONCLUSIONS: Both (125)I and (106)Ru eye plaque brachytherapy treatment result in encouraging tumor control for patients with uveal melanoma. We demonstrate that (106)Ru offers these benefits with reduced toxicity in patients treated for uveal melanomas ≤5 mm in apical height.
Authors: Hasan Danish; Matthew J Ferris; Ehsan Balagamwala; Jeffrey M Switchenko; Kirtesh R Patel; Maria Choudhary; Caroline Craven; Pia Mendoza; John Suh; Chris Bergstrom; Hans E Grossniklaus; Thomas M Aaberg; Arun Singh; Ian R Crocker; Mohammad K Khan Journal: Melanoma Res Date: 2018-04 Impact factor: 3.599
Authors: Charlotte A Espensen; Ane L Appelt; Lotte S Fog; Anita B Gothelf; Juliette Thariat; Jens F Kiilgaard Journal: Cancers (Basel) Date: 2019-08-06 Impact factor: 6.639
Authors: Luca Tagliaferri; Monica Maria Pagliara; Carlotta Masciocchi; Andrea Scupola; Luigi Azario; Gabriela Grimaldi; Rosa Autorino; Maria Antonietta Gambacorta; Antonio Laricchiuta; Luca Boldrini; Vincenzo Valentini; Maria Antonietta Blasi Journal: J Contemp Brachytherapy Date: 2017-12-30